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Azelaic acid was successfully used in the clinical treat-
ment of 7 cases of lentigo maligna in that remission of 
the lesions was observed in all our patients. In order to 
elucidate mechanism(s) of the beneficial clinical effects, 
w-e studied the effect of azelaic acid on cultured mela-
noma cells. 
Cell numbers recovered from melanoma cell cultures 
grown for several days in the presence of 10 mM azelaic 
acid were 50-70% less than those recovered from con-
trol cultures or from cultures containing 10 mM adipic 
acid. This reduction of cell n u mbers was not due to a 
simple cytotoxic or cytolytic effect of azelaic acid but 
rather due to a dose-dependent inhibition of DNA syn-
thesis. Interestingly, nontoxic concentrations of azelaic 
acid, which significantly reduced DNA synthesis of cul-
tured melanoma cells, had no overt effect on the protein 
synthesis of these cells. It is conceivable that inhibition 
of DNA synthesis is one of the mechanisms by which 
azelaic acid prevents growth and proliferation of abnor-
mal melanocytes. 
Azelaic acid (1,7-heptanedicarboxylic acid, nonanedioic acid) 
is a straight-chained, saturated dicarboxylic acid. Based on the 
observation that C8-C"' dicarboxylic acids act as competitive 
inhibitors of mushroom tyrosinase in vitro [1,2], Nazzaro-Porro 
et al used a 15% azelaic acid cream to topically treat lesions of 
lentigo maligna and observed clinica l and histologic remission 
of the lesions in all patients studied [3,4]. These authors 
suggested that inhibition of tyrosinase activity was responsible 
for the in vivo effects of azelaic acid in lentigo maligna (3]. 
This assumption was challenged by studies of Pathak eta! (5] 
in the guinea pig system, which demonstrated that azelaic acid 
represented only a poor depigmentating agent. Moreover, re-
cent evidence exists [ 6, 7] that (1) after incubation of melanoma 
cells with radioactively labeled dicarboxylic acids, the radioac-
tivity is main ly incorporated into mitochondria and nuclei and 
that (2) C8- C12 dicarboxylic acids may inhibit various mito-
chondrial enzymes. On the basis of all these observations one 
may argue that azelaic acid exerts its biologic effects via inter-
action with various intracellular targets. We therefore felt that 
simultaneous assessment ofthe effects of azelaic acid on various 
functional and phenotypical features of abnormal melanocytes 
might provide a better understanding of the beneficial effects 
of this compound in the treatment of disorders characterized 
by melanocyte dysfunction . 
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MATERIALS AND METHODS 
Clinicopathologic Studies 
Seven patients with lentigo maligna (LM) were t reated twice dai ly 
by topical application of 20% azelaic ac id cream (Schering AG , West 
Berlin, F.R.G.) to the area of the lesions for various t ime periods. 
Patient selection criteria included: (1) la rge size of lesion which would 
have necessitated a major surgical in te rvention; (2) histopathologic 
evidence obtained from a representative biopsy that t he les ion was 
noninvas ive (Clark level 1) ; (3) old age of patients (over 70 years) . The 
study was approved by the Inst itutional Ethical Committee and in-
formed consent was obtained from the patients. 
In an attempt not to unreasonably reduce the size of the lesions 
studied and in order to prevent intlammatory stimuli possibly caused 
by mult iple biops ies , biopsies were taken only before and afte r cessation 
of t reatment and processed for histopathologic and, in some instances 
electron microscopic studies. ' 
Cell Culture 
Two melanoma cell lines, G-361 (human origin) , and clone M-3 of 
the mouse Cloudman S-91 melanoma (S-91/ M-3) were obtained from 
t he American Type Culture Collection, Rockville, Maryland and grown 
in monolayer cultures for several passages in our laboratory before use. 
For compa rative analysis the human lymphoblasto id Raji-cellline was 
propagated in our laboratory. Raji cells were mainta ined in medium 
RPMI 1640 (Flow Laboratories, Rockville , Maryland) whereas G-361 
were grown in McCoy's 5a medium (Flow) and S-91 / M-3 in Hams' F-
lO medium (Flow). All media were supplemented with 10% heat-
inactivated feta l calf serum (FCS) and gentamyci n (G ibco, Grand 
Island, New York) . 
Assay for Cell Growth and Viability 
About 2.5 x 105 cells were seeded in 25-cm2 t issue culture tlasks 
(Costar, Cambridge, Massachusetts) in 5 ml volumes. Azelaic acid (C9 ; 
nonanedioic ac id, Schering AG) and for control purposes adipic acid 
(C6; hexanedioic ac id, Serva, Heidelberg, F.R.G.) were dissolved in 
phosphate-buffered saline (PBS), adjusted to pH 7.4, and added to t he 
freshly established cultures to give the desired final concent rations. At 
24- h in te rvals, cells of t riplicate cultures were mechanica lly detached 
with a rubber policeman, combined with the free-tloating ce lls, and 
counted with a hemocytometer. Cell viabi lity was assessed by trypan 
blue exclusion. 
Adipic acid was chosen as a control drug since we wanted to compare 
the effects of aze laic acid with the effects of a substance of s imilar 
molecular configuration. Additionally, preliminary studies with a panel 
of dicarboxylic ac ids (C.-C10, data not shown) have shown that adip ic 
acid is the longest-chained dicarboxylic ac id with no profound effects 
on mela noma cell growth. In all experiments, either azelaic acid or 
adipic ac id were continuously present throughout the ent ire culture 
period. 
Protein- and DNA -Synthesis 
For determination of protein synthesis G-361 melanoma cells were 
harvested wit h a rubber policeman and were carefully washed. Cells 
(3 x 105 to 5 X 105) were resuspended in 5 ml methionine-free minimum 
essent ia l medium (MEM) (G ibco) contai ning 10% heat-inactivated, 
dia lyzed FCS, glutamine, gentamycin, 5% McCoy's medium, and 1.25 
J.L Ci [35Sjmethionine (New England Nuclear, NEN, Boston, Massachu -
setts, 800- 1000 Ci/ mmol) and incubated with or without the respective 
dicarboxylic acids (final concent rations ranging from 10- 40 mM) for 4 
and 16 h, respectively, at 3TC/5% C02• For the evaluation of DNA 
synthesis, G-361 melanoma ce lls were t reated as described above with 
the exception that supplemented McCoy's medium wi th 35 J.L Ci [3HJ 
thymidine (NEN, 70- 80 Ci/ mmol) was used as incubation medium for 
internal labeling. [3H]Thymidine and dicarboxylic acids were added to 
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freshly split cells or to ce lls which were cultured for 20 h after splitting 
and incubation was performed for 4 and 8 h, respectively. After the 
respective incubation ti mes, cells were harvested, washed, and the rate 
of protein and DNA synthesis was determined by measuring the incor-
porat ion of ["5S]methionine and [3H]thymidine, respectively, into tri-
chloroacetic acid (TCA)-precipi table material as described by Wait he 
and Hirschhorn [8 ]. All experiments were done in triplicates and values 
standardized on numbers of living cell s. Standard deviations were 
always smaller than 15%. 
For the evaluation of DNA synthesis by epidermal cells, C3H/He 
mouse epidermal cells were prepared by trypsinization of ear skin as 
described recently [9 ]. Cells (6 X 105) per determination were washed 
and suspended in 5 ml RPM! 1640 medium (G ibco), supplemented with 
10% FCS, 35 11Ci ["H]thym idine (70- 80 Ci/mmol), and vary~g 
amounts of azelaic acid and adipic ac id, respectively. Afte r incubatiOn 
at 37" C for 4 h, the cells were harvested and the DNA synthesis 
evaluated as described above. 
Polyacrylamide Gel Electrophoresis (PAGE) 
G-362 melanoma ce lls, incubated for 16 h at 37"C with [35S]methi-
onine as described above, were lysed by a 2-min incubation in sodium 
dodecyl sulfate (SDS)-sample buffer (0.1 M Tris-HCI, pH 6.8; 4% 
glycerol, 2% SDS; 2% mercaptoethanol , 0.004% bromophenol blue) in 
a boilin g-water bath. Following centrifugation 10-111 aliquots we~e elec-
trophoresed in a discont inuous electrophoresis system as descnbed by 
Laemmli [ 10] . Gels were placed in a solution of 0.1 % Coomassie 
Brilliant Blue R/10% acetic acid/50% methanol. After 16 h gels were 
destained in 15% acetic acid, 10% methanol for an addit ional 20 h, 
transferred to concentrated acetic ac id, and then incubated in enhancer 
solu t ion (10% 2,5-diphenyloxazole in acetic ac id). Fluorographic analy-
sis using Kodak X-Omat XS-5 film was done according to Laskey and 
Mills [11]. 
Cell-Free Protein Synthes is 
Epidermal cell suspensions were prepared from trunk and ear skin 
from C3H/ He mice (Zentralanstalt fur Versuchstierzucht, Himberg, 
Austria) as recently described [9] . RNA was isolated from 5 x 108 ce lls 
by phenol /chloroform and ethanol precipitation as described previously 
[J 2]. Yeast mRNA was purchased from NEN. Cell -free protein synthe-
sis (1- 5 11g mRNA per sample) was carried out in the presence of [358 ] 
methionine according to Pelham and Jackson [1 3[ with reagents pro-
vided by NEN as previously described [1 4) . Following trans lation , 10 
J.Lg bovine serum albumin (BSA) was added to each sample and proteins 
were precipitated by the addition of 1 X vol12% TCA, 0.1 % methion ine. 
The precipi tates were collected on Whatman OF /C glass fiber filters 
and washed 6 times with 10 ml 6% TCA, 0.1 % methionine. Filters were 
assayed for radioactivity in a Beckman liquid scintillation counter, 
Type 6800 a lte r treatment with 80% Protosol (NEN). 
RESULTS 
Clim:cal Investigations 
Topical treatment twice da ily of 7 patients with histologically 
proved LM with a 20% azelaic acid cream resulted in complete 
clinical remiss ion of LM lesions in a ll patients after 9-12 
months of t reatmen t (Fig lA,B). Apart from a transitory, mild 
inl1ammatory reaction after initiation of t herapy and some 
desquamation, treatment with azelaic acid was well tolerated 
and no side effects of e ither tox ic o r allergic nature were 
observed. Clinica l improvement manifested as progressive dim-
inut ion of th e in ten s ity of pigmentation and s ize of t he lesion. 
Treatment was discontinued when complete disappearance of 
pigmented spots indicated clinical remission. At t his time a 
second biopsy specimen was taken from the previously involved 
sites a nd processed for histopathology and electron microscopy. 
After cessatio n of aze la ic ac id treatment, patients were seen by 
two of us (H.P., K.W.) at bimonthly intervals . After follow-up 
observation periods ra nging from 2- 13 months, no signs of 
recurrence were disclosed in any of the 7 patients. 
Histopathology 
The biopsy specimens from a ll 7 patients exhibited the 
diagnostic criteria of LM (Fig 1C). There was a proliferation 
of atypical melanocytes on the basal layer of the epidermis and 
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FIG 1. Patient J.K., male, age 75 years (1 of 7 representat ive cases). 
A, Clinical appearance- before treatment: coi n-sized nonhomogenous, 
brownish, irregularly shaped lentigo maligna on the left cheek. B, 
Clinical appearance- after t reatment: complete resolution of t he lesion 
after topical azelaic acid cream treatment for 9 months. C, Histopath-
ology- before t reatment: atypical melanocytes are seen both singly and 
in irregular nests in the basal layer of the epidermis. The papillary 
dermis conta ins a lymphohistiocytic infiltrate with some melanophages 
(H & E, X 325). D, Histopathology- after t reatment: t he biopsy from 
t he previously involved skin shows a normally organized epidermis 
with slight hyperkeratosis, hypergranulosis, and acanthosis; a few 
melanophages are seen in the upper derm is (H & E, x 250). E, Electron 
microscopy- before t reatment: the nucleus of a melanocyte is enlarged, 
shows deep indentations, and exhibits a prominent nucleus; an in-
creased number of (morphologically abnormal) melanosomes is present 
in t he cytoplasm (X 7500; bar= l11m). F, Electron microscopy- after 
treatment: the nucleus of a melanocyte appears rounded and displays 
a regu lar chromatin pattern; the cytoplasm contains fewer organelles 
than seen in pretreatment specimens (X 11,000; ba.r = 1 J.Lm) . 
in the upper parts of the adnexal epithelium. The m elano-
cytes-either spindle-shaped or more epitheloid in morphol-
ogy- were seen both singly and in irregula r nests; the upper 
parts of the epidermis were free from these cells. The papillary 
dermis showed solar elastosis and a dense irregula rly distrib-
uted lymphohistiocytic infiltrate with a prominent number of 
melanophages. There were no tumor cells invading t he dermis. 
After the treatment with azelaic acid (Fig 1D) the biopsy from 
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t he previously involved skin showed a normally organized epi-
dermis wit h s light hype rkeratosis and hypergranulosis and a 
moderate acanthosis. The melanocytes appeared normal in size 
a nd shape. Melanophages were still present in t he papillary 
dermis. 
Ultrastructural Findings 
The electron microscopic changes in t he lesions following 
treatment with azela ic acid were similar to t hose previously 
descri bed (3]. Before azelaic acid t reatment (Fig 1E), biopsies 
from LM lesions displayed an increased number of melanocytes 
of irregu lar size and shape seen s ingly and/or in small groups 
in t he lower layers of t he epidermis. The la rge nuclei of t he 
melanocytes showed deep indentations and several nuclear 
profiles were frequently seen in one cell; the nucleoli were ve ry 
prominent. The cytoplasm varied in its amount and in the 
composition of the organelles. Melanosomes a nd premelano-
somes were present in the cytoplasm and in t he dendritic 
process in an increased number; frequently they were morpho-
logically abnormal in t hat t hey appeared in different sizes and 
exhibited a bizarre morphology including ring-forms. By con-
t rast, posttreatment biopsies (Fig 1F) exhibited a strikingly 
different morphology. The melanocytes were normal in number 
a nd size. They occurred as singles a nd although sometimes 
more closely spaced, t hey were never clustered in groups. Their 
nuclei were round with a rather normal-appearing chromatin 
pattern, t heir cytoplasm appeared reduced in amount with 
fewer organelles in comparison to t he pretreatment specimens. 
The melanosomes were still numerous and in all stages of 
maturation but abnormal structural variants were not seen. 
T he surrounding keratinocytes appeared activated with many 
ribosomes and polyribosomes in t heir cytoplasm. The basal 
la mina exhibited multip le reduplications. 
Effect of Azelaic Acid on Growth Kinetics 
G-361 melanoma cell cul tures were ini t iated at a seeding 
density of 0.25 X 106 cells/cul ture flask. When grown eit her in 
medium alone or in the presence of 10 mM adipic acid, we 
regularly observed a 5- to 6-fold increase in cell numbers after 
7 days of cu lture. In sharp contrast, cell numbers recovered 
from G-361 melanoma cell cultures grown in t he presence of 
10 mM azelaic acid were approximately 50- 70% less t han t hose 
recovered from melanoma cell cult ures grown in either medium 
or 10 mM adipic acid. Azelaic acid (1 mM) or adipic acid (1 mM) 
had no overt effect on the cell numbers of G-361 melanoma 
cells (Fig 2A ). At the ini t iation of t he culture, G-361 melanoma 
cells were 70- 90% viable as determined by trypan blue exclu-
sion. Throughout the ent ire cul ture period (7 days) significant 
differences in viability among the various treatment groups 
were not encounte red. 
The adverse effect of 10 mM azelaic ac id on the growth rate 
but not on cell viability of melanoma cells was even more 
pronounced when S-91/M-3 mouse melanoma cell s were tested: 
starting cell numbers and recovered cell numbers after 2, 4, and 
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nearly identical. Again 1 mM azelaic acid or 10 mM and 1 mM 
adipic acid had no effect on the cell growth (Fig 2B ). In order 
to determine the threshold of overt cytotoxicity of azelaic acid, 
G-361 melanoma cells were grown in azelaic acid concentra-
t ions ranging from 20- 100 mM. Although melanoma cells grown 
in t he presence of 20 or 40 mM azelaic acid were equally viable 
as the controls after 4 h of culture, differences in cell viability 
emerged after 48 h of culture. Whereas 20 mM azelaic acid did 
not overtly affect the cell viabi lity, 40 mM or 100 mM azelaic 
acid resulted in a 70-99% decrease of cell viabi li ty as compared 
to control cu ltures (data not shown). Thus, clearly, azelaic acid 
action on cell viability is a time- and dose-dependent p henom-
enon. 
In order to test the cell-type specificity of the inhibitory 
effect of azelaic acid on t he growth rate of cells, lymphoblastoid 
Raji cells were grown in t he presence or absence of 10 mM 
azelaic acid or adipic acid. In analogy to our observations with 
melanoma cells, neither azelaic acid nor adipic acid led to 
alterations in cell viabi lity. However, after on ly 3 days of 
culture, cell numbers recovered from cultures containing 10 
mM azelaic acid were 60-80% lower than t hose collected from 
control cul tures i.e., medium alone or with 10 mM adipic acid 
(data not shown) . 
DNA Synthesis 
In order to clarify whether t he azelaic acid- induced reduction 
of cell numbers was preceded by an inhibition of DNA synthe-
sis, either freshly spli t or 20-h precultured adherent G-361 
human melanoma cells were incubated in t he presence of [3H] 
t hymidine and dicarboxylic acids. After 8 h the [3H]thymidine 
incorporation of precultured cells into TCA-precipitable ma-
terial was inhibited in a dose-dependent fashion by azelaic acid. 
Adipic acid had a slight inhibitory effect but 4 times as much 
needs to be added to get a similar effect to azelaic acid (Fig 3). 
The inhibitory action of azelaic acid on DNA synthesis was 
also found after incubating freshly split G-361 melanoma cells 
for 4 h with azelaic acid at concentrations of 10-40 mM (Fig 4). 
Since significant diffe rences in cell numbers were not observed 
unti l 12 h of cultivation of G-361 melanoma cells in the pres-
ence of dicarboxylic acid (data not shown), reduction of cell 
proliferation by azelaic acid is clearly preceded by a consider-
able inhibition of DNA synthesis. This finding supports the 
suggestion that azelaic acid acts primarily on DNA-dependent 
proliferative capacity of melanoma cells. 
On the other hand, when cul tures of murine epidermal cells 
were incubated for 4 h and tested for DNA synthesis capacity, 
we found no influence of azelaic acid and adipic acid, respec-
t ively, in concentrations up to 40 mM (Table 1). However, it 
should be mentioned that in our primary murine epidermal cell 
cu ltures t he DNA synt hesis reaches a plateau between 4 and 
16 h. Since one cannot exclude the possibility that a putative 
action of azelaic acid (or adipic acid or both) on DNA synthesis 
by keratinocytes would require the exposure of these cells to 
the drug(s) for more than 4 h, a possible effect of dicarboxylic 
acids on the de novo DNA synthesis would escape our detection. 
6 
F IG 2. Growth kinetics of mela-
noma cell lines. Human G-361 (A) and 
mouse (S-91/M-3) (B) melanoma cells 
were grown in the presence or absence 
of various concentrations of azelaic 
acid or adipic acid and cell numbers 
were determined after distinct time in · 
tervals. Values are the means of tripli · 
cates of 1 of 3 representat ive experi· 
ments . ._.=Azelaic acid 10- 2 M · 
0 ···--0 = azelaic acid 10- 3 M; •--4 
= adipic acid 10- 2 M; 6. ·- · ·-6. = adipic 
acid 10-3 M;___.= medium control. 
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TABLE I. DNA synthesis of murine epidermal cells 
Control 
Azelaic acid 10 mM 
20 mM 
40mM 





3.1 ± 0.3 
3.4 ± 0.2 
3.2 ± 0.4 
3.2 ± 0.5 
3.2 ± 0.1 
3.2 ± 0.3 




Murine epidermal cells were isolated by trypsinization [9]. After 6 h 
in the presence of [3H]thymidine and dicarboxylic acids, cells were 
harvested and the incorporation of [3H)thymidine into TCA-precipit-
able material was determined and standardized on numbers of living 




FtG 3. DNA synthesis of G-361 melanoma cells. G-361 melanoma 
cells were seeded in culture fl asks and after 20 h various concentrations 
of azelaic acid and adipic acid, respectively, were added. After 8 h in 
the presence of 1"1-1 }thymidine, cells were harvested and the incorpo-
ration of l"H]thymidine into TCA-p recipilable material was deter-
mined. Values are sta ndardized on numbers of living cells and are the 













FIG 4. DNA and protein sy nthesis of G-361 melanoma cells. G-361 
melanoma cells were freshly seeded and grown in medium containing 
l"H]thymidine (DNA synthesis) or I"''S ]methionine (protein synthesis) 
in the presence or absence of various concentrations of azelaic acid 
(C9) for 4 h. The incorporation of l"H]t.hymidine into DNA and I""S] 
methionine into protein, respectively, was determined. A =Control; B 
= o.o1 M c,; c = o.o2 M c.; D = o.o4 M c,. 
Protein Synthesis 
In order to lind out whether azelaic acid concentrations that 
lead to a considerable inhibition of DNA synthesis also inter-
fere with other major metabolic pathways, the int1uence of this 
dicarboxylic acid on protein synthesis of human melanoma 
cells was evaluated. No differences in the rate of the synthesis 
of total cell protein as measured by the incorporation of [35S1 
methionine into TCA-precipitable material was observed after 
a 4-h incubation of G-361-melanoma cells in the presence of 
various concentrations of azelaic acid (Fig 4 ). Moreover, neither 
azelaic ac id nor ad ipic acid reduced the rate of protein synthesis 






FtG 5. Protein synthesis of G-361 melanoma cells. G-361 melanoma 
cells were grown for 16 h in medium containing [35S]methionine in 
absence (A), and continuous presence of 10 mM azelaic acid (B) and 
adipic acid (C), respectively. Cells were harvested, lysed in SDS sample 
buffer, and analyzed by SDS-PAGE and fluorography as described in 
Materials and Methods. Molecular weight standards (D) were 14C-
labeled myosin (205 kD), phosphorylase B (97 kD) , bovine serum 
albumin (69 kD), egg albumin (46 kD), and carbonic an hydrase (30 
kD ). 
during a 12-h exposure of G-361 melanoma cells (control group 
32.8 ± 0.4 nmol [35S]methionine/106 cells vs 31.0 ± 0.6 and 31.8 
± 1.6 nmol/106 cells for 20 mM azelaic acid and 20 mM adipic 
acid, respectively). Also, no int1uence of azelaic acid and adipic 
acid, respectively, on the patterns of biosynthetically labeled 
G-361 melanoma cell proteins could be detected by SDS-PAGE 
(Fig 5). 
In addition, inability of azelaic acid and adipic acid to inhibit 
protein synthesis was further demonstrated by t he use of a cell-
free translation system. Using epidermal RNA and yeast 
mRNA, respectively, no inhibition of translation could be de-
tected in the presence of dicarboxylic acids (Fig 6) . 
DISCUSSION 
Confirming the observations of Nazzaro-Porro et al [3] a 
clinical remission of LM was observed in all our patients after 
9-12 months of treatment. Remission of the lesions was accom-
panied by the disappearance of abnormal melanocytes as con-
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Yeast mRNA (A) or epidermal RNA (B) 
was translated in the presence of [35S] 
methionine in a rabbit reticulocyte sys-
tem in the presence or absence of various 
concentrations of azelaic acid (C9 ) and 
adipic acid (C6), respectively. Protein 
synthesis was measured by determining 
the incorporation of [35S]methionine 
into TCA-precipitable material. Values 
are the means of duplicates (SD less than 
10%). Column.~ A = control; B = 0.01 M 
c.; c = o.oo1 M c.; D = o.ooo1 M c.; E 





firmed by histopathology and by electron microscopy. Contrast-
ing wit h this clinicopathologic phenomenon, there ex ist cur-
rently no conclusive data on the mechanism of the disappear-
ance of abno rmal melanocytes fo llowing azelaic acid treatment. 
The rather high doses (20%) of topically applied azelaic acid 
required to induce clinical remissions raise t he question as to 
whether t he azelaic ac id effect is cytotoxic in nature. Such a 
cytotoxic effect may be either nondiscriminatory (acting on all 
cells) or, a lte rnatively, may affect abnormal melanocytes in a 
selective fashion. The fo rmer possibility appears unlikely in 
t h at in our and other [3] clinicopathologic studies fran k epi-
dermal necrosis was never observed. T he latter possibility 
w hich is favored by several investigators [3,15,16) cannot be 
excluded with certain ty but appears unlikely since t reatment 
periods from 9- 12 months are required to induce complete 
clinicopathologic remission of the disease. 
Since these observations indicate that cytolysis of malignant 
melanocytes is probably not responsible for the clinical effects 
seen, we established an in vitro system which would permit us 
to examine the effects of azelaic acid on melanoma cells under 
nontoxic condit ions. We tested the effects of various concen-
trations of azelaic ac id on viability and growth of two melanoma 
cell lines. Whereas azelaic acid concentrations ranging from 
40- 100 mM resulted in a sharp decline of cell viabi lity within 
48 h and were thus too high fo r further studies, concentrations 
of 10- 20 mM did not overtly affect cell viabili ty but led to a 
significant reduction in the growth rate of melanoma cells. 
Therefore it was reasonable to assume that- in a nontoxic dose 
range- azelaic acid leads to metabolic alterations causing de-
creased proliferation. In fact, our experiments clearly showed 
that 10- 20 mM azelaic acid , but not adipic acid, when contin-
uously present in melanoma cell cultures leads to a pronounced 
decrease in DNA synthesis without adversely affecting cell 
v iabili ty. 
One might sti ll argue at this point that the observed inhibi-
tion of DNA synthesis by azelaic acid does not represent a 
selective effect on DNA but rather reflects t he impairment of 
other metabolic functions. However, at concentrations of 10-
40 mM (concentrations which reduced DNA synthesis) azelaic 
acid had no measurable effect on the overall protein synthesis 
of human melanoma cells exposed for cu lture periods from 4-
48 h. The possibility still exists that long-period incubation of 
melanoma cells with high (i.e., toxic) doses of azela ic acid might 
nonetheless result in an inhibition of both DNA and protein 
synthesis. This could lead to sudden cell death and might 
therefore exp la in our finding t hat 40- 100 mM azelaic acid 
results in a dramatic reduction in the viability of cultured 
melanoma cells. Since incorporat ion of radiolabeled amino 
acids into protein is standardized on numbers of living cells, 
sudden cell death due to a combined reduction of DNA and 
protein synthesis might explain why we fai led to detect any 
effect of azelaic acid on protein synthesis even after long-period 
incubation. 
T he azelaic acid effect on the DNA synthesis and growth 
kinetics of melanoma cells is not specific for these cells as a 
similar antiproliferative effect was observed with Raji cells. By 
contrast, 10- 40 mM azelaic acid does not inhibit DNA synthesis 
of cultured keratinocytes, which is in keeping with the obser-
vations that in vivo application of azelaic acid cream does not 
overtly influence the growth and differentiation of keratino-
cytes, as judged by clinical and histopathologic criteria. Assum-
ing then that under in vivo conditions azelaic acid preferentially 
affects malignant melanocytes within the epidermis, one may 
speculate that t his could result from enhanced uptake mecha-
nisms operative in these cells. Cells susceptible to azelaic acid 
might possess enhanced diffusion uptake mechanisms or spe-
cific receptors for dicarboxylic acids in analogy to what has 
been recently reported for retinoids [17) . 
In summary, our data demonstrate that nontoxic concentra-
tions of azela ic acid reduce melanoma cell growth in cu lture 
and that this effect is preceded and paralleled by an inhibition 
of DNA synthesis. We further speculate that a threshold con-
centration of azelaic acid is sufficient to arrest the growth of 
only abnormal, highly proliferative melanocytes which would 
result in a shortened in vivo life span and/ or possibly, in a 
higher susceptibi lity of these cells to host defense mechanisms. 
This might in turn lead to the destruction of these cells and 
might explain the beneficial effects of azelaic acid on LM. 
We thank Mr. G. Steiner for excellent technical assistance and Miss 
G. Schreinmoser and Miss H. Jeffrey for secretarial work provided 
during the course of preparation of th is manuscript. 
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